An Effective Therapy to Painful Bone Metastases: Cryoablation Combined with Zoledronic Acid

详细信息    查看全文

• 作者：Fenqiang Li ; Wenhui Wang ; Li Li ; Yaowen Chang ; Dongjun Su…
• 关键词：Pain ; Bone metastases ; Cryoablation ; Zoledronic acid ; Combined therapy ; Efficacy
• 刊名：Pathology & Oncology Research
• 出版年：2014
• 出版时间：October 2014
• 年：2014
• 卷：20
• 期：4
• 页码：885-891
• 全文大小：179 KB
• 参考文献：1. Yoh K, Kubota K, Ohmatsu H, Goto K, Niho S, Ohe Y (2012) Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases. Anticancer Res 32:4131-135
  2. Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A (2012) Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res 18:4841-849 CrossRef
  3. Fujino M, Suzuki K, Nishio M, Nishiyama N, Osaka Y (2011) Strategy of radiation therapy for bone metastases and MSCC in breast cancer patients. Breast Cancer 18:238-43 CrossRef
  4. Saylor PJ, Lee RJ, Smith MR (2011) Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 29:3705-714 CrossRef
  5. Woodward E, Jagdev S, McParland L, Clark K, Gregory W, Newsham A, Rogerson S, Hayward K, Selby P, Brown J (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48:160-66 CrossRef
  6. Lien K, Zeng L, Zhang L, Nguyen J, Di Giovanni J, Popovic M, Jamani R, Cramarossa G, Culleton S, Chow E (2012) Predictive factors for well-being in advanced cancer patients referred for palliative radiotherapy. Clin Oncol (R Coll Radiol) 24:443-51 CrossRef
  7. Smith HS, Barkin RL (2014) Painful boney metastases. Am J Ther 21:106-30
  8. Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A (1992) Samarium- 153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 33:1451-458
  9. Smith HS (2011) Painful osseous metastases. Pain Physician 14:E373–E403
  10. Callstrom MR, Atwell TD, Charboneau JW, Farrell MA, Goetz MP, Rubin J, Sloan JA, Novotny PJ, Welch TJ, Maus TP, Wong GY, Brown KJ (2006) Painful metastases involving bone: percutaneous image-guided cryoablation –prospective trial interim analysis. Radiology 241:572-80 CrossRef
  11. Callstrom MR, Dupuy DE, Solomon SB, Beres RA, Littrup PJ, Davis KW, Paz-Fumagalli R, Hoffman C, Atwell TD, Charboneau JW, Schmit GD, Goetz MP, Rubin J, Brown KJ, Novotny PJ, Sloan JA (2013) Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial. Cancer 119:1033-041 CrossRef
  12. Choi J, Raghavan M (2012) Diagnostic imaging and image-guided therapy of skeletal metastases. Cancer Control 19:102-12
  13. Casta?eda Rodriguez WR, Callstrom MR (2011) Effective pain palliation and prevention of fracture for axial-loading skeletal metastases using combined cryoablation and cementoplasty. Tech Vasc Interv Radiol 14:160-69 CrossRef
  14. de Freitas RM, de Menezes MR, Cerri GG, Gangi A (2011) Sclerotic vertebral metastases: pain palliation using percutaneous image-guided cryoablation. Cardiovasc Intervent Radiol 34(Suppl 2):S294–S299 CrossRef
  15. Callstrom MR, Charboneau JW (2007) Image-guided palliation of painful metastases using percutaneous ablation. Tech Vasc Interv Radiol 10:120-31 CrossRef
  16. Paparella S, Finkelberg E, Varisco D, Tondelli E, Rocco F (2011) Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications. Urologia 78:300-04 CrossRef
  17. Yamada K, Yoshimura M, Kaise H, Ogata A, Ueda N, Tokuuye K, Kohno N (2012) Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases. Exp Ther Med 3:226-30
  18. Saad F, Eastham J (2010) Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 76:1175-181 CrossRef
  19. Ishiwata T, Hirose T, Hirama M, Miura K, Iwakami S, Tominaga S, Adachi M, Takahashi K (2011) A feasibility study of zoledronic acid combined with carboplatin/nedaplatin plus paclitaxel in patients with non-small cell lung cancer with bone metastases. Tumori 97:568-72
  20. Lopez-Olivo MA, Shah NA, Pratt G, Risser JM, Symanski E, Suarez-Almazor ME (2012) Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer 20:2985-998 CrossRef
  21. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ (1994) Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330:592-96 CrossRef
  22. Foro Arnalot P, Fontanals AV, Galcerán JC, Lynd F, Latiesas XS, de Dios NR, Castillejo AR, Bassols ML, Galán JL, Conejo IM, López MA (2008) Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother Oncol 89:150-55 CrossRef
  23. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM (2001) Clinical importance of changes in chronic pain intensity measured on an 11- point numerical pain rating scale. Pain 94:149-58 CrossRef
  24. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100:2613-621 CrossRef
  25. Pozzi S, Raje N (2011) The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist 16:651-62 CrossRef
  26. Fu D, He X, Yang S, Xu W, Lin T, Feng X (2011) Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro. BMC Musculoskelet Disord 12:146 CrossRef
  27. Insalaco L, Di Gaudio F, Terrasi M, Amodeo V, Caruso S, Corsini LR, Fanale D, Margarese N, Santini D, Bazan V, Russo A (2012) Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. J Cell Mol Med 16:2186-195 CrossRef
  28. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I (2009) Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 8:2821-832 CrossRef
  
• 作者单位：Fenqiang Li (1)
  Wenhui Wang (1)
  Li Li (1)
  Yaowen Chang (1)
  Dongjun Su (1)
  Gang Guo (1)
  Xuewen He (1)
  Mingxiang Li (1)
  
  1. The Department of Interventional Medicine, the First Hospital of Lanzhou University, No.1 Donggang West Road, Lanzhou, 730000, China
  
• ISSN：1532-2807

文摘

Approximately half or more of patients diagnosed with late malignant tumors may suffer from metastatic bone pain, effective palliation of pain becomes an important part of comprehensive therapy for malignant tumors. In this study, we examined the efficacy and safety of the combined regimen of cryoablation and zoledronic acid in patients of bone metastatic pain. A total of 84 subjects were randomly divided into three groups, and underwent treatments of cryoablation plus zoledronic acid, cryoablation alone, zoledronic acid alone between June 2009 and March 2012. Patients responses had been assessed for a total of 6?months by using the Brief Pain Inventory (BPI)-Short Form. The results showed that the mean response of worst and average pain significantly dropped at week 2 (all P--.05) in group with cryoablation treatment but at week 4 (all P--.05) in group with zoledronic acid treatment. While between week 16 and week 24, zoledronic acid treatments showed more durable response to worst and average pain compared to cryoablation (all P--.05). Cryoablation plus zoledronic acid regimen showed significant drop in worst and average pain between week 1 and week 4 compared to zoledronic acid alone (all P--.05) and more durable effect on bone metastatic pain between week 12 and week 24 than cryoablation alone (all P--.05). Additionally, no serious adverse effects and complication were observed by this combination use. In conclusion, cryoablation combined with zoledronic acid was safe and effective regimen and showed its superiority of fast response and durable effect on painful bone metastases.